Loading
Life sciences · Journal article
Frontiers in Pharmacology · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Therapies targeting the epidermal growth factor receptor (EGFR) cause a spectrum of cutaneous toxicities that can compromise quality of life, treatment adherence, and cancer-treatment continuity. Persistent and phenotype-specific toxicities create a need for evidence-based adjunctive interventions. Purpose Our aim was to appraise product-specific clinical and mechanistic evidence for Chinese botanical drugs in EGFR-targeted therapy-associated cutaneous toxicity and to define priorities for translational development. Methods We conducted a structured narrative search of PubMed, Web of Science Core Collection, and Scopus from inception to 7 May 2026. Evidence was classified by the highest supporting design, from controlled human studies to indirect non-EGFR or computational evidence. We appraised directness, internal validity, product characterisation, outcome measurement, precision, and reporting completeness. Results and Discussion Direct human evidence for defined Chinese botanical drugs remains insufficient to establish clinical efficacy. Available studies are limited by small samples, heterogeneous products, variable background care, and incomplete reporting. EGFR-specific experimental studies provide low-certainty support for barrier injury, inflammatory amplification, and phenotype-relevant mechanisms. Evidence from non-EGFR models, isolated metabolites, and network analysis remains hypothesis-generating. Conclusion Defined Chinese botanical drugs should be evaluated only as adjuncts to standard supportive care. Progress will require standardised products, phenotype-stratified trials, prespecified patient-relevant and mechanistic outcomes, and complete reporting of safety and anticancer-treatment continuity.